Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy
This is the report of the clinical case of a patient who presents the association of a JAK-2 positive chronic myeloproliferative neoplasia to a subsequent 5q- myelodysplastic syndrome, developed after about 14 years from the first diagnosis. Patient’s symptoms had rapidly worsened, and she became tr...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2016-10-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2622 |
id |
doaj-a32bf44538ca4fac89b05b81058a8889 |
---|---|
record_format |
Article |
spelling |
doaj-a32bf44538ca4fac89b05b81058a88892020-11-24T23:02:30ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062016-10-0180e2016050e201605010.4084/mjhid.2016.0501644Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapyAntonella Vaccarino0Irene Dogliotti1Fabio Marletto2Andrea Demarchi3Mario Bazzan4Rare Diseases, Immunology, Immunohaematology and Haematology Department, Turin, ItalyUniversity of Turin, ItalyRare Diseases, Immunology, Immunohaematology and Haematology DepartmentPathology Unit, San Giovanni Bosco Hospital, Turin, ItalyRare Diseases, Immunology, Immunohaematology and Haematology Department, Turin, ItalyThis is the report of the clinical case of a patient who presents the association of a JAK-2 positive chronic myeloproliferative neoplasia to a subsequent 5q- myelodysplastic syndrome, developed after about 14 years from the first diagnosis. Patient’s symptoms had rapidly worsened, and she became transfusion-dependent. Therapy with low-dose Lenalidomide quickly reduced the splenomegaly, and completely brought white cells counts, haemoglobin and platelets back to normal. After more than one year from start, blood cell count is still normal. As far as we know this is the first case of an effective treatment with Lenalidomide reported in this clinical setting.http://www.mjhid.org/index.php/mjhid/article/view/2622myeloproliferative syndrome, myelodysplastic syndrome, 5q deletion, JAK-2 mutation, lenalidomide |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Antonella Vaccarino Irene Dogliotti Fabio Marletto Andrea Demarchi Mario Bazzan |
spellingShingle |
Antonella Vaccarino Irene Dogliotti Fabio Marletto Andrea Demarchi Mario Bazzan Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy Mediterranean Journal of Hematology and Infectious Diseases myeloproliferative syndrome, myelodysplastic syndrome, 5q deletion, JAK-2 mutation, lenalidomide |
author_facet |
Antonella Vaccarino Irene Dogliotti Fabio Marletto Andrea Demarchi Mario Bazzan |
author_sort |
Antonella Vaccarino |
title |
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy |
title_short |
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy |
title_full |
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy |
title_fullStr |
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy |
title_full_unstemmed |
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy |
title_sort |
diagnosis of del(5q) mds, 14 years after jak-2 positive pv appearance: complete remission of both diseases with lenalidomide monotherapy |
publisher |
PAGEPress Publications |
series |
Mediterranean Journal of Hematology and Infectious Diseases |
issn |
2035-3006 |
publishDate |
2016-10-01 |
description |
This is the report of the clinical case of a patient who presents the association of a JAK-2 positive chronic myeloproliferative neoplasia to a subsequent 5q- myelodysplastic syndrome, developed after about 14 years from the first diagnosis. Patient’s symptoms had rapidly worsened, and she became transfusion-dependent. Therapy with low-dose Lenalidomide quickly reduced the splenomegaly, and completely brought white cells counts, haemoglobin and platelets back to normal. After more than one year from start, blood cell count is still normal. As far as we know this is the first case of an effective treatment with Lenalidomide reported in this clinical setting. |
topic |
myeloproliferative syndrome, myelodysplastic syndrome, 5q deletion, JAK-2 mutation, lenalidomide |
url |
http://www.mjhid.org/index.php/mjhid/article/view/2622 |
work_keys_str_mv |
AT antonellavaccarino diagnosisofdel5qmds14yearsafterjak2positivepvappearancecompleteremissionofbothdiseaseswithlenalidomidemonotherapy AT irenedogliotti diagnosisofdel5qmds14yearsafterjak2positivepvappearancecompleteremissionofbothdiseaseswithlenalidomidemonotherapy AT fabiomarletto diagnosisofdel5qmds14yearsafterjak2positivepvappearancecompleteremissionofbothdiseaseswithlenalidomidemonotherapy AT andreademarchi diagnosisofdel5qmds14yearsafterjak2positivepvappearancecompleteremissionofbothdiseaseswithlenalidomidemonotherapy AT mariobazzan diagnosisofdel5qmds14yearsafterjak2positivepvappearancecompleteremissionofbothdiseaseswithlenalidomidemonotherapy |
_version_ |
1725636456779612160 |